nfected do not show symptoms, but fatigue, abdominal pain and nausea can be common. The current standard treatment of care, peginterferon and ribavirin, is effective in about half of all patients treated. Treatment outcomes vary based on a number of factors including genotype, viral load, genetic factors, stage of liver disease, co-infections and ability to adhere to treatment. According to the Centers for Disease Control, HCV affects an estimated 3.2 million Americans.
About Romark Laboratories
Romark Laboratories, L.C. (www.romark.com) is a biopharmaceutical company committed to the discovery and development of innovative new small molecules for treating infectious diseases and cancers.
(1) Rossignol JF, Elfert A, El-Gohary Y, et al. Improved virologic response in patients with chronic hepatitis C genotype 4 treated with nitazoxanide plus peginterferon alfa-2a with or without ribavirin. Gastroenterology. 2009;136:856-862.
(2) Rossignol JF, Elfert A, Keeffe EB. Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide. J Clin Gastroenterol. In press.
(3) Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009; 284:29798-29808.
(4) Korba BE, Montero AB, Farrar K, et al. Nitazoxanide, tizoxanide, and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antivir Res. 2008;77:56-63.
Page: 1 2 3 4 5 Related biology technology :1
|SOURCE Romark Laboratories, L.C.|
Copyright©2010 PR Newswire.
All rights reserved
. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States2
. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer3
. Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco4
. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 20085
. Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C6
. Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan7
. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients8
. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 269
. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering10
. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.11
. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets